Immunotherapy for renal cell carcinoma

Area of Science:

• Oncology
• Immunology
• Urology

Background:

• Renal cell carcinoma (RCC) is resistant to traditional chemotherapy and radiation.
• Immunotherapy is a key treatment for metastatic RCC, with various approaches explored.
• Current immunotherapies achieve some antitumor responses but have limited long-term efficacy.

Purpose of the Study:

• To outline the principles of cell-mediated tumor immunotherapy for RCC.
• To review clinical trials investigating immunotherapy for RCC.
• To discuss the role of immune regulation in RCC treatment.

Main Methods:

• Review of existing literature on RCC immunotherapy.
• Analysis of clinical trial data for cytokine-, antigen-, and dendritic cell-based therapies.
• Discussion of immune regulatory mechanisms involving antigen-presenting cells (APC) and regulatory T cells (Treg).

Main Results:

• Multiple clinical trials highlight the safety and effectiveness of various immunotherapies for RCC.
• Antitumor immune responses and clinically significant outcomes have been observed.
• Low response rates and limited long-term improvement remain challenges.

Conclusions:

• Immunotherapy is crucial for metastatic RCC management due to treatment resistance.
• Immune regulation by APC and Treg cells is increasingly recognized as important.
• Further research into optimizing immunotherapy and understanding immune regulation is needed for improved RCC patient outcomes.